Singapore markets closed

Esperion Therapeutics, Inc. (ESPR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
12.49+0.40 (+3.31%)
At close: 4:00PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 5353.19M
Enterprise value 3648.59M
Trailing P/E N/A
Forward P/E 1-2.48
PEG Ratio (5 yr expected) 1-0.07
Price/sales (ttm)5.69
Price/book (mrq)N/A
Enterprise value/revenue 310.44
Enterprise value/EBITDA 7-2.34

Trading information

Stock price history

Beta (5Y monthly) 1.07
52-week change 3-66.60%
S&P500 52-week change 335.11%
52-week high 339.49
52-week low 310.99
50-day moving average 313.23
200-day moving average 321.18

Share statistics

Avg vol (3-month) 3702.34k
Avg vol (10-day) 31.5M
Shares outstanding 528.28M
Implied shares outstanding 6N/A
Float 26.15M
% held by insiders 11.58%
% held by institutions 1104.66%
Shares short (30 Aug 2021) 48.1M
Short ratio (30 Aug 2021) 413.32
Short % of float (30 Aug 2021) 440.23%
Short % of shares outstanding (30 Aug 2021) 428.63%
Shares short (prior month 29 Jul 2021) 49.02M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Jun 2021


Profit margin 0.00%
Operating margin (ttm)-447.89%

Management effectiveness

Return on assets (ttm)-56.93%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)62.11M
Revenue per share (ttm)2.32
Quarterly revenue growth (yoy)-80.80%
Gross profit (ttm)78.22M
EBITDA -277.55M
Net income avi to common (ttm)-324.52M
Diluted EPS (ttm)-12.14
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)219.19M
Total cash per share (mrq)7.75
Total debt (mrq)514.6M
Total debt/equity (mrq)N/A
Current ratio (mrq)3.33
Book value per share (mrq)-11.58

Cash flow statement

Operating cash flow (ttm)-292.16M
Levered free cash flow (ttm)-216.39M